Literature DB >> 9778271

Malignant glioma: who benefits from adjuvant chemotherapy?

L M DeAngelis1, P C Burger, S B Green, J G Cairncross.   

Abstract

We combined two randomized prospective Brain Tumor Study Group data sets to analyze the effects of prognostic factors on survival by treatment group. Adjuvant chemotherapy increased long-term survival regardless of prognostic factors. Pathological review revealed that oligo dendrogliomas were overrepresented among long-term survivors independent of therapy. Prognostic factors do not predict benefit from adjuvant nitrosourea in malignant gliomas, and long-term survival with chemotherapy is not explained by oligodendroglial tumors.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9778271     DOI： 10.1002/ana.410440418

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


  30 in total

1.  Pediatric supratentorial high-grade glioma: multicenter retrospective observational study of the Korean Society for Pediatric Neuro-Oncology.

Authors:  Tae-Young Jung; Ji Yeoun Lee; Dong-Seok Kim; Hyeon Jin Park; Chae-Yong Kim; Young-Shin Ra; Mee-Jeong Lee; Seong-Ho Kim; Hee-Jo Baek; Il Han Kim; Kyung Duk Park; Seung-Ki Kim
Journal:  J Neurooncol       Date:  2014-11-04       Impact factor: 4.130

2.  Dendritic cells pulsed with total tumor RNA for activation NK-like T cells against glioblastoma multiforme.

Authors:  Prachya Vichchatorn; Adisak Wongkajornsilp; Sawang Petvises; Sumalee Tangpradabkul; Samart Pakakasama; Suradej Hongeng
Journal:  J Neurooncol       Date:  2005-11       Impact factor: 4.130

Review 3.  Molecular imaging of brain tumors: a bridge between clinical and molecular medicine?

Authors:  B J Schaller; M Modo; M Buchfelder
Journal:  Mol Imaging Biol       Date:  2007 Mar-Apr       Impact factor: 3.488

4.  Improved anti-tumor effect of liposomal doxorubicin after targeted blood-brain barrier disruption by MRI-guided focused ultrasound in rat glioma.

Authors:  Lisa H Treat; Nathan McDannold; Yongzhi Zhang; Natalia Vykhodtseva; Kullervo Hynynen
Journal:  Ultrasound Med Biol       Date:  2012-07-19       Impact factor: 2.998

5.  Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial.

Authors:  Il Han Kim; Chul-Kee Park; Dae Seog Heo; Chae-Yong Kim; Chang Hun Rhee; Do-Hyun Nam; Seung Hoon Lee; Jung Ho Han; Se-Hoon Lee; Tae Min Kim; Dong-Wan Kim; Jeong Eun Kim; Sun Ha Paek; Dong Gyu Kim; In Ah Kim; Yu Jung Kim; Jee Hyun Kim; Byung-Joo Park; Hee-Won Jung
Journal:  J Neurooncol       Date:  2010-11-04       Impact factor: 4.130

6.  Success at last: a molecular factor that informs treatment.

Authors:  Andrew B Lassman
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

Review 7.  Applications of neural and mesenchymal stem cells in the treatment of gliomas.

Authors:  Thomas Kosztowski; Hasan A Zaidi; Alfredo Quiñones-Hinojosa
Journal:  Expert Rev Anticancer Ther       Date:  2009-05       Impact factor: 4.512

Review 8.  Experience with irinotecan for the treatment of malignant glioma.

Authors:  James J Vredenburgh; Annick Desjardins; David A Reardon; Henry S Friedman
Journal:  Neuro Oncol       Date:  2008-09-10       Impact factor: 12.300

9.  Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times.

Authors:  C Goetz; P Riva; G Poepperl; F J Gildehaus; A Hischa; K Tatsch; H J Reulen
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

10.  Maintenance therapy with 13-cis retinoid acid in high-grade glioma at complete response after first-line multimodal therapy--a phase-II study.

Authors:  Caecilia Wismeth; Peter Hau; Klaus Fabel; Ulrike Baumgart; Birgit Hirschmann; Horst Koch; Tanja Jauch; Oliver Grauer; Lisa Drechsel; Alexander Brawanski; Ulrich Bogdahn; Andreas Steinbrecher
Journal:  J Neurooncol       Date:  2004-05       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.